Drugmaker Baxalta is working with bankers to buy a U.S.-based hematology and oncology specialist valued at about $2 billion.» Read More
"You're going to have some wins and some that don't turn out," J&J chief Alex Gorsky tells CNBC. "But overall we're very confident."
Jeffrey Marrazzo, Spark Therapeutics CEO, and Dr. Jean Bennett, Spark Therapeutics advisor, discuss how advances in gene therapy are changing the way rare diseases are treated. And Gordon Gund, Gund Investment Corp. CEO, weighs in.
CNBC's Meg Tirrell breaks down all the biotech data coming out ahead of the ASCO Conference, and why Clovis Oncology's stock is climbing.
A new study suggests Viagra can fight malaria, which still infects millions and kills half a million people every year.
U.S. scientist Bill Nye, popularly known as "the Science Guy", has launched a Kickstarter to fund an satellite propelled by solar energy.
CNBC's Meg Tirrell takes a look at new cancer-fighting drugs and other therapies in the pipeline.
The American Society of Clinical Oncology conference will occur at the end of May in Chicago. CNBC's Meg Tirrell reports which companies investors should watch. Also, Les Funtleyder, ESquared Asset Management, shares his view.
Pedialyte is going after a new market, and they don't have a bedtime...
Ahead of the world's biggest cancer research conference, the American Society of Clinical Oncology meeting, here are the companies to watch.
More than half a million Americans have annual prescription drug costs of more than $50,000.
A panel of outside advisers of the FDA recommended approval for Vertex Pharma's cystic fibrosis drug, reports CNBC's Meg Tirrell.
If successful, Moderna Therapeutics' cutting-edge drug method could be used to fight cancer and some infectious diseases.
Moderna Therapeutics' CEO Stephane Bancel discusses the company's discovery of utilizing messenger RNA, which helps to direct the body's own cells to build proteins and fight rare diseases.
Potent animal hormones used in livestock farming are sticking around in the environment far longer than had been expected.
The U.S. government said health insurers must cover all FDA-approved methods of birth control without co-pays or charges to the patient.
This company has raised $1 billion to develop the Holy Grail in drugs: Have the body's own cells churn out proteins to fight disease.
European lawmakers to debate scrapping animal testing, a move which could spell trouble for the pharma industry, experts have warned.
Britain's GlaxoSmithKline is to collaborate with U.S. scientists in developing a cure for AIDS.
A development in how patient requests for experimental drugs are handled could be a big step in health care, said a medical director Thursday.
Top-rated biotech analyst Mark Schoenebaum weighs in on latest mega-deal & bubble talk.
Get the best of CNBC in your inbox